BioNTech Showcases Promising Late-Stage Lung Cancer Portfolio with New Clinical Data at ELCC 2026
BioNTech presents new ELCC 2026 data underscoring the strength and differentiation of its late-stage lung cancer pipeline BioNTech has announced that it will showcase new clinical data from its expanding…
Dupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid (BP)
Dupixent Approved in Japan as the First Targeted Therapy for Adults with Bullous Pemphigoid Regeneron Pharmaceuticals and Sanofi have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has…
AbbVie Becomes Official Pharmaceutical Partner of Major League Baseball
AbbVie Becomes Official Pharmaceutical Partner of Major League Baseball AbbVie has unveiled a landmark multi-year partnership with Major League Baseball (MLB), officially naming the company as the league’s “Official Pharmaceutical…
Celltrion Unveils KRW 1.2 Trillion Expansion of Songdo Drug Substance Facilities, Boosting Total Capacity to 570,000 Liters
Celltrion unveils KRW 1.2 trillion Songdo expansion, boosting DS production capacity by 180,000L to a total of 570,000L Celltrion has unveiled an ambitious and far-reaching investment strategy aimed at significantly…
Eylea 8 mg Secures Approval in Japan for a Third Retinal Disease Indication
Eylea™ 8 mg Secures Approval in Japan for Its Third Retinal Disease Indication The Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization in Japan for Eylea 8…
Bristol Myers Squibb Highlights Camzyos Data in oHCM at ACC 2026
Bristol Myers Squibb Strengthens Position in Obstructive Hypertrophic Cardiomyopathy with New Camzyos (mavacamten) Data Presented at ACC 2026 Bristol Myers Squibb has unveiled an extensive body of new clinical and…
Pfizer and Valneva Report Strong Phase 3 VALOR Trial Results for Lyme Disease Vaccine Candidate Demonstrating High Efficacy
Pfizer and Valneva Report Positive Phase 3 VALOR Results Showing High Efficacy for Lyme Disease Vaccine Candidate Pfizer Inc. and Valneva SE have announced encouraging topline findings from the pivotal…
Roche Opens New Institute of Human Biology to Advance Drug Discovery
Roche Launches State-of-the-Art Institute of Human Biology Facility to Advance Next-Generation Human Model Systems in Drug Discovery and Development Roche has officially inaugurated a new state-of-the-art research facility to serve…
Curi Bio and Battelle Partner to Advance Neuromuscular Pharmacology Innovations
Curi Bio and Battelle Forge Strategic Alliance to Advance New Approach Methods in Neuromuscular Pharmacology Curi Bio, a recognized leader in the development of human-relevant three-dimensional (3D) tissue platforms, has…
ImmunityBio Secures Macau Approval for ANKTIVA® to Treat BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors
ImmunityBio Secures Macau SAR Authorization for ANKTIVA® in BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors ImmunityBio, today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special…
KalVista to Showcase New EKTERLY® Data at 2026 Global Angioedema Conference
KalVista Pharmaceuticals to Showcase New Clinical Data on EKTERLY® (Sebetralstat) at the 2026 Global Angioedema Leadership Conference KalVista Pharmaceuticals has announced a significant scientific presence at the upcoming 2026 Global…
Newron to Showcase Latest Advances at the 2026 Schizophrenia International Research Society Annual Congress 2026
Newron Showcases Latest Research at the 2026 Schizophrenia International Research Society Annual Congress 2026 Newron Pharmaceuticals S.p.A., a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for disorders affecting the…